Aspire BioPharma is trading 6.6% higher at $8.88, with no clear catalyst identified.
- No new company-specific announcement, filing, earnings release, or regulatory catalyst was identified for September 24, 2026.
- The September 9 share-repurchase authorization predates today’s move.
- Biotech-sector weakness and mixed broader markets do not clearly explain the gain.